AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE

Dazodalibep Demonstrated Statistically Significant and Clinically Meaningful Improvement in Systemic Disease Activity Results Support the Potential for a New, Highly Differentiated Treatment Option for People Living With a Debilitating Autoimmune Disease THOUSAND OAKS, Calif., Sept. — Company newsroom — sourced from Amgen. Matter furnished by the company. Not a Notice Nearby paid placement. This page reprints a substantial excerpt from the official release. Read the original for the full text. Read the original: https://investors.amgen.com/news-releases/news-release-details/amgen-announces-positive-topline-phase-3-results-dazodalibep